Document Detail


10mM glucosamine prevents activation of proADAMTS5 (aggrecanase-2) in transfected cells by interference with post-translational modification of furin.
MedLine Citation:
PMID:  19909832     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Glucosamine has been previously shown to suppress cartilage aggrecan catabolism in explant cultures. We determined the effect of glucosamine on ADAMTS5 (a disintegrin-like and metalloprotease domain (reprolysin type) with thrombospondin type-1 motifs 5), a major aggrecanase in osteoarthritis, and investigated a potential mechanism underlying the observed effects.
DESIGN: HEK293F and CHO-K1 cells transiently transfected with ADAMTS5 cDNA were treated with glucosamine or the related hexosamine mannosamine. Glucosamine effects on FURIN transcription were determined by quantitative RT-PCR. Effects on furin-mediated processing of ADAMTS5 zymogen, and aggrecan processing by glucosamine-treated cells, were determined by western blotting. Post-translational modification of furin and N-glycan deficient furin mutants generated by site-directed mutagenesis was analyzed by western blotting, and the mutants were evaluated for their ADAMTS5 processing ability in furin-deficient CHO-RPE.40 cells.
RESULTS: Ten mM glucosamine and 5-10mM mannosamine reduced excision of the ADAMTS5 propeptide, indicating interference with the propeptide excision mechanism, although mannosamine compromised cell viability at these doses. Although glucosamine had no effect on furin mRNA levels, western blot of furin from glucosamine-treated cells suggested altered post-translational modification. Glucosamine treatment led to decreased glycosylation of cellular furin, with reduced furin autoactivation as the consequence. Recombinant furin treated with peptide N-glycanase F had reduced activity against a synthetic peptide substrate. Indeed, site-directed mutagenesis of two furin N-glycosylation sites, Asn(387) and Asn(440), abrogated furin activation and this mutant was unable to rescue ADAMTS5 processing in furin-deficient cells.
CONCLUSIONS: Ten mM glucosamine reduces excision of the ADAMTS5 propeptide via interference with post-translational modification of furin and leads to reduced aggrecanase activity of ADAMTS5.
Authors:
D R McCulloch; J D Wylie; J-M Longpre; R Leduc; S S Apte
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-11-04
Journal Detail:
Title:  Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society     Volume:  18     ISSN:  1522-9653     ISO Abbreviation:  Osteoarthr. Cartil.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-02-22     Completed Date:  2010-07-30     Revised Date:  2011-07-25    
Medline Journal Info:
Nlm Unique ID:  9305697     Medline TA:  Osteoarthritis Cartilage     Country:  England    
Other Details:
Languages:  eng     Pagination:  455-63     Citation Subset:  IM    
Copyright Information:
Copyright 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Affiliation:
Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH 44195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ADAM Proteins / drug effects*
Blotting, Western
Cells, Cultured
Furin / drug effects*
Glucosamine / metabolism*
Humans
Protein Processing, Post-Translational
Reverse Transcriptase Polymerase Chain Reaction
Statistics as Topic
Grant Support
ID/Acronym/Agency:
AR49930/AR/NIAMS NIH HHS; R01 AR049930-04/AR/NIAMS NIH HHS; R01 AR049930-05/AR/NIAMS NIH HHS; R56 AR049930-06A2/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
3416-24-8/Glucosamine; EC 3.4.21.75/Furin; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.-/ADAMTS5 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingd...
Next Document:  Developing, regulating, and ethically evaluating new technologies in otolaryngology-head and neck su...